Patents by Inventor Tamon Hayashi

Tamon Hayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
    Patent number: 8460886
    Abstract: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood, after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
    Type: Grant
    Filed: July 3, 2009
    Date of Patent: June 11, 2013
    Assignees: Ono Pharmaceutical Co., Ltd., Medarex, Inc.
    Inventors: Shiro Shibayama, Takao Yoshida, Tamon Hayashi, Akio Hayashi, Jun Murai
  • USE OF AN EFFICACY MARKER FOR OPTIMIZING THERAPEUTIC EFFICACY OF AN ANTI-HUMAN PD-1 ANTIBODY ON CANCERS
    Publication number: 20110123550
    Abstract: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
    Type: Application
    Filed: July 3, 2009
    Publication date: May 26, 2011
    Applicants: ONO PHARMACEUTICAL CO., LTD., MEDAREX, INC.
    Inventors: Shiro Shibayama, Takao Yoshida, Tamon Hayashi, Akio Hayashi, Jun Murai